Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MMD WILL BACK ONCOGENE SCIENCE’s TRANSCRIPTION-BASED HEART DRUG RESEARCH

Executive Summary

MMD WILL BACK ONCOGENE SCIENCE's TRANSCRIPTION-BASED HEART DRUG RESEARCH under a cardiovascular research collaboration announced Dec. 14. Marion Merrell Dow will receive worldwide marketing and manufacturing rights to gene transcription-based cardiovascular drugs that Oncogene Science develops. Oncogene Science will retain rights to any cardiovascular diagnostic products developed and receive a royalty on any resultant drug sales. Under the agreement, Marion Merrell Dow will purchase $6 mil. in Oncogene Science stock (an approximately 7% stake) and supply $11 mil. in license fees and research funding to the Uniondale, N.Y.-based firm. MMD's equity investment will consist of approximately 1.1 mil. shares at $5.50 per share. After the transaction with MMD, Oncogene Science will have 16.2 mil. shares of common stock outstanding. MMD will also receive warrants for an additional 500,000 shares at $5.50 per share. The research venture will focus on developing drugs for hypertension, atherosclerosis and restenosis, Oncogene Science said. Oncogene has been researching possible applications of gene transcription technologies to cardiovascular diseases for about two years, the company said. No drug candidates have yet been identified. The biotechnology firm has existing collaborative agreements with Pfizer, Wyeth-Ayerst and Becton Dickinson. The most extensive collaboration is the firm's six-year-old venture with Pfizer, renewed in late 1990, in the area of cancer drugs ("The Pink Sheet" Dec. 24, 1990, p. 26). Pfizer will hold just under 4% of Oncogene Science stock following Marion Merrell Dow's stock purchase. A four-year venture formed in December 1991 with American Home Products focuses on developing small-molecule drugs for asthma, diabetes, osteoporosis and immune system modulation ("The Pink Sheet" Jan. 6, T&G-4). In addition, Oncogene Science has a collaboration with Becton Dickinson in oncogene-related cancer diagnostic development. That deal was renewed in the fall of 1991, after a three-year hiatus, when Oncogene Science acquired Applied Biotechnology ("The Pink Sheet" May 27, 1991, T&G-12).

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel